About BillionToOne, Inc.

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: 713
Price: $99.03
Previous close: $102.73
Market capitalization: $4.63B
Volume: 605,946
P/E ratio: 142.18
52-week low: $61.96
52-week high: $150.44

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.